Mycoplasma arthritidis, an agent of chronic proliferative arthritis of rodents, secretes a potent soluble superantigen, MAM, that is active for both murine and human T and B lymphocytes. We now report the complete nucleotide and amino acid sequence of MAM and show it to be distinct from other proteins and not closely related phylogeneticaUy to other superantigens. Two functional domains on MAM are identified based on the ability ofpeptides encompassing these regions to inhibit lymphocyte proliferation by the intact MAM molecule. One of these domains shares short sequences or epitopes with other microbial superantigens. The second domain contains the consensus legume lectin motif-B, which is important for T cell activation by concanavalin (Con) A. MAM and Con A peptides containing this motif are functionally cross reactive, suggesting a novel secondary pathway for T cell activation by MAM.
S
uperantigens are potent immunomodulatory molecules that are produced by a number of pathogenic bacteria (1, 2) , endogenous murine retroviruses (3) , and may be associated with HIV-1 (4, 5) . Superantigens have been hypothesized to play a role in human diseases including Kawasaki's disease, toxic shock syndrome, rheumatoid arthritis, and diabetes (6) (7) (8) . The Mycoplasma arthritidis mitogen (MAM) ~ (9) is a particularly interesting superantigen as it is produced by an organism that causes spontaneous chronic arthritis in rodents (10) . Furthermore, evidence suggests that MAM triggers autoimmune arthritis in collagen-injected mice by activating the specific T cells that drive the inflammatory response (11) .
MAM is a typical superantigen in that it is presented to murine and human T cells by direct binding to MHC molecules present on accessory cell surfaces and is recognized by specific V~ chain segments of the TCR without MHC restriction (9) . Although MAM is much less potent in activating human T cells than are the Staphylococcus aureusderived superantigens, unlike the latter it promotes a strong polyclonal B cell activation in human PBL. This property suggests that MAM may be an ideal model for the study of 1Abbreviations used in this paper: MAM, Mycoplasma arthtitidis mitogen; SEA, SEB, SEC, staphylococcal enterotoxin A, B, and C, respectively. the role of superantigens in the pathogenesis of human autoimmune disease characterized by hypergammaglobulinemia (12) . We show here that MAM is a unique protein, phylogenetically distinct from other superantigens, but which contains cross-reactive motifs found in other T cell mitogens.
Materials and Methods
Cloning and Sequencing of MAM. Degenerate oligonucleotide primers were designed corresponding to the NH 2-and COOHterminal ends of the previously sequenced peptide (13) , based upon the codon usage ofMycoplasma capricolum (14) . These primers were used to amplify, by PCtL, chromosomal DNA from M. arthritidis strain PG6. The PCIL product was labeled with 32p and used to screen an M. arthtitidis PG6 genomic library constructed in EMBL3 using previously described methods (15) . Three clones were detected, and restriction enzyme analysis of these clones showed that mare was contained within a 1.4-kbp XbaI fragment that was subcloned into the plasmid pTZ18IL (Pharmacia Biotech Inc., Piscataway, NJ) and sequenced by use of the Sanger dideoxy chain termination method (15) .
Analysis of Physical Properties Of MAM. The algorithms of Garnier et al. (16) and Chou and Fasman (17) were used to predict the secondary structure for MAM. Hopp and Wood's (18) method predicted hydrophilicity values. Secondary structure and hydrophilicity analyses were performed using the DNASIS v. 2.0 (Hitachi Software, San Bruno, CA) sequence analysis software.
Peptide Blocking of Lymphocyte Proliferation. Proliferation of BALB/c splenocytes was measured in a microtiter plate assay at 72 h after a 24 h pulse with [3H]TdR as detailed previously (19) . For blocking, MAM peptides at 0.25-1 mg/ml were incubated with lymphocytes for 1 h at 37~ before addition of a 1:20,000 dilution (approximately ~<50 pg/ml) of pure MAM in complete RPMI 1640 medium. Due to insolubility, peptide 10 was not tested. To determine whether the inhibitory peptides were toxic, they were incubated at the above concentrations with a B cell lymphoma (2PK-3), two T cell hybridomas (one MAM reactive, V~38.2, and one MAM nonreactive, V~3) and L929 fibroblasts in a 28-h assay using an 8- 
VI3
Usage by Native and Recombinant MAM. V~ usage by MAM and other control superantigens was measured by IL-2 production by specific V~ TCR-bearing T hybridomas in the presence of ",/-irradiated 2PK-3 AC (both at 10 s cells/ml). Vol (KSEA), V~3 (5KC), and V~11 (1BVBll-17.7) were kindly provided by Dr. P. Marrack (National Jewish Center, Denver, CO), V136 by Dr. B Huber (Tufts University, Boston, MA), and Vf38.2 (2Hd-11.2) by Dr. B. Araneo (University of Utah, Salt Lake City, UT).
Methods have been described (20) . Sequence Analysis. Superantigen amino acid sequences were obtained from the current PIP. and Swiss-protein databases, from ho et al. (21) , and our sequence data for MAM. All were aligned using the ClustalV algorithm (D. Higgins, European Molecular Biology Laboratory) using default settings. The DDMATKIX application of the IntelliGenetics (IntelliGenetics, Inc., Mountain View, CA) package was used to search for regions of homology between MAM and other superantigens/mitogens using the Jimenez-Montano similarity alphabet for amino acid homology. A search for moti8 in MAM was conducted using the Motifs program in the GCG sequence analysis software package (Madison, WI). Aligned sequences were examined using an heuristic search in PAUP 3.0 (David Swofford, Illinois National History Survey, Champaign, IL), and the best-fit unrooted dendogram was saved.
Results and Discussion
Previously, MAM was purified to homogeneity, and the sequence of the first 53 amino acids of the mature protein was obtained by Edman degradation (13) . This sequence was used to design primers to generate a PCR product probe for screening of an M. arthritidis genomic library. It should be noted that the PCR product, when sequenced and translated, gave the amino acid sequence previously obtained by Edman degradation. The probe identified three EMBL3 clones containing mam. The gene was subcloned, and the nucleic acid sequence was determined (Fig.  1 ). The nucleic acid sequence was translated in the reading frame giving the amino acid sequence previously determined by Edman degradation. MAM begins with the methionine codon at nucleotide 127 and ends at nucleotide 766. A p-independent transcriptional termination region was predicted using the Termination program contained within the GCG sequence analysis software package. The three UGA universal stop codons at amino acid positions 132, 177, and 178 were read as tryptophans based on the codon usage for the Mycoplasmatales (14) . After converting these stop codons to UGG tryptophan codons, the fulllength, mature MAM protein encoded by nucleotides 127-766 was expressed in Escherichia coli and purified by methods to be described (Knudtson, K.L., M. Manohar, and B.C. Cole, manuscript in preparation). This recombinant protein (rMAM) was biologically similar to native MAM and showed an identical VI3 usage that was distinct from that of other superantigens (Table 1) .
MAM was predicted to be a protein of 213 amino acids with a calculated molecular weight of 25, 193 . This is similar to the values reported for the staphylococcal and streptococcal superantigens (6) . However, the calculated pI of 10.1 makes MAiM the most basic of the known bacterial superantigens. The MAM sequence does not contain cysteine residues, and so the disulfide bond, present in most "Native MAM and recombinant MAM (rMAM) were tested at ~ ~50 ng/ml, SEA and SEB at 5 t~g/ml, and Con A at 15 I*g/ml. *Not tested.
other superantigens, cannot be formed. Since MAIM is a secreted product (9), we sought evidence of a signal peptide.
Upstream of the mature protein start site there is encoded a 25-amino acid peptide that possesses most of the characteristics that define bacterial signal peptides (22) (Fig. 1) . Moreover, just further upstream is a potential ribosomal binding site, the sequence of which complements the 3'-OH end of the 16S rRNA ofM. arthritidis (23) . Previously, it was reported that culture supernatants from 32 strains of M. arthritidis all possessed mitogenic activity (13) . The presence of the mare gene in these strains was confirmed by the ability of primers to the 5' and 3' ends of the gene to generate the appropriate "-%50-bp product by PC1L (data not shown). MAM and its gene were found to be unique because protein and gene database searches failed to identify similar sequences. The 27% G + C content of mam is consistent with that of most mycoplasma genomes (14) , but is also similar to that of the staphylococcal and streptococcal toxin genes. Considering a common origin for these genes, we conducted a phylogenetic analysis comparing the amino acid sequences of MAM and other superantigens. MAM was not closely related to other superantigens and alone occupied one of three main branches on an unrooted phylogram (not shown). The closest similarity was between MAM and streptococcal pep M5 (24) at 24% sequence similarity.
To identify active domains on MAM, a series of overlapping MAM peptides were synthesized (Fig. 2) and tested for their ability to inhibit lymphocyte proliferation by native MAM (Fig. 3) . Two candidate functional domains were identified. The first, represented in peptides 2A (MAMls_31) and 2B (MAM11_38) inhibited MAM-induced proliferation in a dose-dependent manner (Fig. 3) , but had no effect on proliferation induced by Con A, indicating that MAM peptide 2 was not toxic (data not shown). The second, peptide 5 (MAM71_95) also blocked MAM activity (Fig. 3) , but also inhibited proliferation induced by Con A by 50% (Fig. 4) . The inhibition by MAM71_9s was not due to toxicity, as subsequent addition of Con A restored the proliferative responses to the values obtained with Con A alone (Fig. 4) . In addition, neither MAMas_31 nor MAM71_95 suppressed the growth of B or T hybridomas or L929 cells (data not shown).
Although MAM was not closely related to other superantigens, searches for common sequences revealed that several superantigens shared potential epitopes with the functional MAM peptide 2 (Fig. 5 A) . Potential epitopes were defined to contain at least four adjacent identical or conserved amino acids followed by additional shared residues separated from the former by no more than three dissimilar residues. Two overlapping alignments of SEB with MAM 11-38 are shown. The SEB region that interacts with MHC molecules comprises a hydrophobic area that includes important residues at SEBa4 ' 45, 47 (25) . This is followed by a hydrophilic or polar region containing SEB67 that is also Figure 4 . Peptide-mediated blocking of lymphocyte proliferation in response to Con A and MAM. MAMvl_gs and Con A2_16 peptides were tested at 0.125-1 mg/ml for ability to block lymphocyte proliferation to MAM at 1:20,000 (~<50 pg/ml) or Con A at 5 ~g/ml. important for M H C binding (26) and which is situated within the shared M A M epitope. As is apparent from Fig.  2 , the M A M peptide 2 has a similar profile, with a hydrophobic area followed by one of hydrophilicity, which lies in a predicted [3 sheet. The region o f similarity between MAM12_29 and the conserved retroviral sequence o f the murine mammary tumor virus 7 (MMTV-7s0_99) (27) is noteworthy since a similar retroviral peptide bound to M H C molecules and competitively blocked the binding of SEA to the same M H C molecules (28) . Regions similar to the retroviral sequence were also present in the SEC superantigens (residues 127-139) (29) and in streptococcal pep M5 toxin (residues 101-112) (24) , although there is no data to suggest that these sequences play a role in the activity of these latter superantigens. A sequence similarity to MAM16.2, 3 was also present in the HIV-1 gp160 envelope glycoprotein, which has recently been shown to exhibit superantigenlike properties (5) and which selectively expands T cells bearing those V~ chain segments that are used by M A M (5, 30) . Regions of similarity between pep M5 and other bacterial superantigens have also been noted (24) .
Whereas few sequence similarities were seen between M A M peptide 5 and other superantigens, a search for m otifs revealed the striking result that MAM, but not other superantigens, contained the seven-residue lectin legume motif [5 consensus sequence present in all legume lectins including Con A. Shown in Fig. 5 B is the consensus legume lectin motif [3, the C o n A2_16 and MAM71_9s peptides, and the motif (shaded) that they contain. Peptide Con A2-16 containing this motif strongly inhibited Con A-induced lymphocyte proliferation (Fig. 4) as well as that mediated by PHA (not shown), confirming that this motif is important for T cell activation. At high concentrations, Con A2-16 also significantly inhibited MAM-induced proliferation (Fig. 4) . Peptide MAM71.gs strongly inhibited MAM-induced lymphocyte activation and partially inhibited that mediated by Con A. Thus the Con A peptide and MAM peptide 5 appear to be functionally cross-reactive. Metal-binding sites within and just downstream of the legume lectin motif 13 (see Fig. 5/3 ) are important in achieving the saccharide bioactive conformation (31, 32) . It is interesting that the motifs in MAM (Fig. 5 B) and Con A are both associated with hydrophobic regions (Fig. 2) of their respective molecules. This suggests that in MAM the motif may serve a similar function by stabilizing the bioactive form of the molecule and/or by configuring a site that interacts with a surface lymphocyte receptor.
In conclusion, MAM is not phylogenetically or structurally closely related to other superantigens on the basis of its linear sequence and a preliminary analysis of its predicted secondary structure. Thus, MAM is the first representative of a new class of superantigen. Despite these major differences, we have presented evidence that short regions of sequence homology may predict functional domains that are common to several superantigens. The domains so identified require confirmation of cross-reactive function. The presence of the legume lectin motif in MAM may indicate that this superantigen alone exhibits a unique interaction site that contributes to lymphocyte activation. Analysis of the x-ray crystallographic structure of MAM and of a library of deletion mutants are now required to more precisely define the molecular interactions that lead to T and B cell superantigenic activity.
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